Literature DB >> 8076762

Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease.

C M Surawicz1, R C Haggitt, M Husseman, L V McFarland.   

Abstract

BACKGROUND/AIMS: Rectal biopsy specimen changes distinguish acute self-limited colitis (ASLC) from idiopathic inflammatory bowel disease (IBD). This study aimed to determine whether these histological criteria are also valid for acute-onset IBD.
METHODS: Blind analysis of colorectal biopsy specimens from 52 patients with ASLC, 51 patients with acute-onset (< 3 months) IBD, and 30 patients with chronic IBD was performed.
RESULTS: Histological features of ASLC are normal crypt architecture and acute lamina propria inflammation, but mixed acute and chronic inflammation can be found. Histological features of IBD are diffusely abnormal crypt architecture, crypt atrophy, mixed lamina propria inflammation, basal plasmacytosis, basal lymphoid aggregates, basal lymphoid hyperplasia, isolated giant cells, epithelioid granulomas, goblet cell mucus depletion, and reactive epithelial hyperplasia. Changes of chronic IBD were present in biopsy specimens as early as 7 days after the onset of symptoms.
CONCLUSIONS: Rectal biopsy specimens are useful in distinguishing ASLC from acute-onset IBD even if the biopsy specimens are not obtained during the first 4 days of the illness. There were no significant differences in histology between acute-onset and chronic IBD.

Entities:  

Mesh:

Year:  1994        PMID: 8076762     DOI: 10.1016/0016-5085(94)90124-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Management of difficult inflammatory bowel disease: where are we now?

Authors:  DS Rampton
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded.

Authors:  Tze S Khor; Hiroshi Fujita; Koji Nagata; Michio Shimizu; Gregory Y Lauwers
Journal:  J Gastroenterol       Date:  2012-02-10       Impact factor: 7.527

3.  Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative.

Authors:  D Jenkins; M Balsitis; S Gallivan; M F Dixon; H M Gilmour; N A Shepherd; A Theodossi; G T Williams
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

4.  Simple objective criteria for diagnosis of causes of acute diarrhoea on rectal biopsy.

Authors:  D Jenkins; A Goodall; B B Scott
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

5.  Mouse model of enteropathogenic Escherichia coli infection.

Authors:  Suzana D Savkovic; Jennilee Villanueva; Jerrold R Turner; Kristina A Matkowskyj; Gail Hecht
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 6.  Ulcerative colitis in children: medical management.

Authors:  David A Gremse; Karen D Crissinger
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue.

Authors:  H S Carlsen; E S Baekkevold; F-E Johansen; G Haraldsen; P Brandtzaeg
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  Audit of the histopathological diagnosis of non-neoplastic colorectal biopsies: achievable standards for the diagnosis of inflammatory bowel disease.

Authors:  A K Dube; S S Cross; A J Lobo
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

Review 9.  Update on chronic diarrhea: a run-through for the clinician.

Authors:  Davinder K Sandhu; Christina Surawicz
Journal:  Curr Gastroenterol Rep       Date:  2012-10

10.  Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.

Authors:  Emina Emilia Torlakovic; Vicki Keeler; Chang Wang; Hyun J Lim; Leslie Ann Lining; Suzanne Laferté
Journal:  BMC Cancer       Date:  2009-07-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.